Oxford Biomedica (LON:OXB) Stock Passes Below 200-Day Moving Average – Here’s Why

Oxford Biomedica plc (LON:OXB) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 631.69 and traded as low as GBX 488. Oxford Biomedica shares last traded at GBX 493, with a volume of 277,370 shares.

Analysts Set New Price Targets

OXB has been the topic of several research analyst reports. Jefferies Financial Group restated a “buy” rating and set a GBX 8.27 target price on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft downgraded Oxford Biomedica to a “hold” rating and lowered their target price for the stock from GBX 800 to GBX 595 in a report on Tuesday. Finally, Royal Bank Of Canada dropped their price target on Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating on the stock in a research note on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 580.85.

Oxford Biomedica Stock Performance

The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. The company has a fifty day moving average price of GBX 585.71 and a 200 day moving average price of GBX 629.11. The stock has a market cap of £608.82 million, a P/E ratio of -18.68 and a beta of 1.10.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.